United Therapeutics Corp
UTHR485.770USD
+8.570+1.80%
Close 11/25, 16:00（ET）Quotes delayed by 15 min
20.84BMarket Cap
16.39P/E TTM
More Details of United Therapeutics Corp Company
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
United Therapeutics Corp Info
Ticker SymbolUTHR
Company nameUnited Therapeutics Corp
IPO dateJun 17, 1999
CEODr. Martine A. Rothblatt
Number of employees1305
Security typeOrdinary Share
Fiscal year-endJun 17
Address1000 Spring St
CitySILVER SPRING
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code20910
Phone13016089292
Websitehttps://www.unither.com/
Ticker SymbolUTHR
IPO dateJun 17, 1999
CEODr. Martine A. Rothblatt
Company Executives of United Therapeutics Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Martine A. Rothblatt
Dr. Martine A. Rothblatt
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
666.42K
--
Mr. Paul A. Mahon, J.D.
Mr. Paul A. Mahon, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
36.78K
--
Mr. Richard A. Giltner
Mr. Richard A. Giltner
Independent Director
Independent Director
20.57K
+6.14%
Prof. Nilda Mesa, J.D.
Prof. Nilda Mesa, J.D.
Independent Director
Independent Director
5.47K
+12.08%
The Hon. Dr. Louis W. Sullivan, M.D.
The Hon. Dr. Louis W. Sullivan, M.D.
Independent Director
Independent Director
3.20K
--
Mr. Michael Benkowitz
Mr. Michael Benkowitz
President, Chief Operating Officer
President, Chief Operating Officer
2.65K
+2.76%
Mr. Christopher Patusky, J.D.
Mr. Christopher Patusky, J.D.
Lead Independent Vice Chairman of the Board
Lead Independent Vice Chairman of the Board
2.59K
+29.50%
Ms. Jan Malcolm
Ms. Jan Malcolm
Director
Director
520.00
-57.38%
Gov. Thomas G. (Tommy) Thompson, J.D.
Gov. Thomas G. (Tommy) Thompson, J.D.
Independent Director
Independent Director
--
--
Mr. Christopher A. Causey
Mr. Christopher A. Causey
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Martine A. Rothblatt
Dr. Martine A. Rothblatt
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
666.42K
--
Mr. Paul A. Mahon, J.D.
Mr. Paul A. Mahon, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
36.78K
--
Mr. Richard A. Giltner
Mr. Richard A. Giltner
Independent Director
Independent Director
20.57K
+6.14%
Prof. Nilda Mesa, J.D.
Prof. Nilda Mesa, J.D.
Independent Director
Independent Director
5.47K
+12.08%
The Hon. Dr. Louis W. Sullivan, M.D.
The Hon. Dr. Louis W. Sullivan, M.D.
Independent Director
Independent Director
3.20K
--
Mr. Michael Benkowitz
Mr. Michael Benkowitz
President, Chief Operating Officer
President, Chief Operating Officer
2.65K
+2.76%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Tyvaso DPI
315.20M
39.47%
Nebulized Tyvaso
168.30M
21.07%
Remodulin
155.70M
19.50%
Orenitram
123.90M
15.51%
Unituxin
61.40M
7.69%
Other
-25.90M
-3.24%
By RegionUSD
Name
Revenue
Proportion
United States
798.60M
100.00%
Rest of World
38.80M
4.86%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Tyvaso DPI
315.20M
39.47%
Nebulized Tyvaso
168.30M
21.07%
Remodulin
155.70M
19.50%
Orenitram
123.90M
15.51%
Unituxin
61.40M
7.69%
Other
-25.90M
-3.24%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.22%
BlackRock Institutional Trust Company, N.A.
9.90%
Renaissance Technologies LLC
5.05%
Avoro Capital Advisors LLC
4.70%
State Street Investment Management (US)
4.47%
Other
65.68%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.22%
BlackRock Institutional Trust Company, N.A.
9.90%
Renaissance Technologies LLC
5.05%
Avoro Capital Advisors LLC
4.70%
State Street Investment Management (US)
4.47%
Other
65.68%
Shareholder Types
Shareholders
Proportion
Investment Advisor
42.03%
Investment Advisor/Hedge Fund
33.78%
Hedge Fund
13.61%
Research Firm
2.96%
Pension Fund
2.92%
Individual Investor
1.84%
Bank and Trust
1.38%
Sovereign Wealth Fund
1.29%
Venture Capital
0.46%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
1348
44.10M
102.42%
-3.87M
2025Q2
1338
46.42M
102.62%
-2.51M
2025Q1
1369
46.67M
103.49%
-1.81M
2024Q4
1344
46.07M
102.60%
-3.00M
2024Q3
1278
45.38M
101.97%
-7.63M
2024Q2
1219
48.02M
108.26%
-2.92M
2024Q1
1151
47.12M
106.59%
-2.41M
2023Q4
1127
46.52M
99.01%
-2.26M
2023Q3
1094
46.35M
98.80%
-3.96M
2023Q2
1068
46.82M
99.96%
-3.45M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
4.43M
9.79%
-8.97K
-0.20%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.34M
9.59%
-138.61K
-3.10%
Jun 30, 2025
Renaissance Technologies LLC
2.12M
4.69%
+12.10K
+0.57%
Jun 30, 2025
Avoro Capital Advisors LLC
2.37M
5.24%
-305.00K
-11.40%
Jun 30, 2025
State Street Investment Management (US)
2.17M
4.79%
-63.20K
-2.83%
Jun 30, 2025
Wellington Management Company, LLP
1.44M
3.19%
-583.48K
-28.79%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.20M
2.65%
-23.63K
-1.93%
Jun 30, 2025
AQR Capital Management, LLC
1.27M
2.82%
+364.71K
+40.15%
Jun 30, 2025
LSV Asset Management
864.62K
1.91%
-37.70K
-4.18%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Simplify Health Care ETF
6.6%
First Trust NYSE Arca Biotechnology Index Fund
4.41%
Formidable Fortress ETF
4.07%
Franklin Genomic Advancements ETF
3.75%
Invesco S&P MidCap Quality ETF
3.64%
Inspire Faithward Mid Cap Momentum ETF
3.64%
Invesco Biotechnology & Genome ETF
3.63%
Invesco Pharmaceuticals ETF
3.62%
VanEck Biotech ETF
3.57%
First Trust NASDAQ Pharmaceuticals ETF
3.44%
View more
Simplify Health Care ETF
Proportion6.6%
First Trust NYSE Arca Biotechnology Index Fund
Proportion4.41%
Formidable Fortress ETF
Proportion4.07%
Franklin Genomic Advancements ETF
Proportion3.75%
Invesco S&P MidCap Quality ETF
Proportion3.64%
Inspire Faithward Mid Cap Momentum ETF
Proportion3.64%
Invesco Biotechnology & Genome ETF
Proportion3.63%
Invesco Pharmaceuticals ETF
Proportion3.62%
VanEck Biotech ETF
Proportion3.57%
First Trust NASDAQ Pharmaceuticals ETF
Proportion3.44%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of United Therapeutics Corp?
The top five shareholders of United Therapeutics Corp are:
The Vanguard Group, Inc. holds 4.43M shares, accounting for 9.79% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.34M shares, accounting for 9.59% of the total shares.
Renaissance Technologies LLC holds 2.12M shares, accounting for 4.69% of the total shares.
Avoro Capital Advisors LLC holds 2.37M shares, accounting for 5.24% of the total shares.
State Street Investment Management (US) holds 2.17M shares, accounting for 4.79% of the total shares.
The Vanguard Group, Inc. holds 4.43M shares, accounting for 9.79% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.34M shares, accounting for 9.59% of the total shares.
Renaissance Technologies LLC holds 2.12M shares, accounting for 4.69% of the total shares.
Avoro Capital Advisors LLC holds 2.37M shares, accounting for 5.24% of the total shares.
State Street Investment Management (US) holds 2.17M shares, accounting for 4.79% of the total shares.
What are the top three shareholder types of United Therapeutics Corp?
The top three shareholder types of United Therapeutics Corp are:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Renaissance Technologies LLC
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Renaissance Technologies LLC
How many institutions hold shares of United Therapeutics Corp (UTHR)?
As of 2025Q3, 1348 institutions hold shares of United Therapeutics Corp, with a combined market value of approximately 44.10M, accounting for 102.42% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -0.20%.
What is the biggest source of revenue for United Therapeutics Corp?
In FY2025Q2, the Tyvaso DPI business generated the highest revenue for United Therapeutics Corp, amounting to 315.20M and accounting for 39.47% of total revenue.
